First approved in 2000, mifepristone is authorized by the Federal Drug Administration (FDA) to be taken in the first ten weeks of pregnancy. On April 7, 2023, the district court granted a preliminary injunction and stayed the FDA's approval of mifepristone. Mifepristone, the Complaint argued, "do[es] not treat serious or life-threatening illnesses" because "pregnancy is a normal physiological state." Should that occur, mifepristone will lose its status as an FDA-approved drug and, as a result, it will be illegal for companies to manufacture, market, or distribute mifepristone. In the interim, if the Fifth Circuit grants the government's stay request, mifepristone will continue to remain available pursuant to the FDA's 2023 REMS guidance while the case remains pending.

Source: New York Times April 26, 2023 09:49 UTC